Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation
Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinic...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sakakura, Kenichi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application - Li, Bao-jia ELSEVIER, 2023, a journal of the American College of Cardiology, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:7 ; year:2014 ; number:10 ; pages:1184-1193 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jcin.2014.04.024 |
|---|
| Katalog-ID: |
ELV033920184 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV033920184 | ||
| 003 | DE-627 | ||
| 005 | 20230625195351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcin.2014.04.024 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014011000015.pica |
| 035 | |a (DE-627)ELV033920184 | ||
| 035 | |a (ELSEVIER)S1936-8798(14)01188-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 600 |a 670 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.45 |2 bkl | ||
| 100 | 1 | |a Sakakura, Kenichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. | ||
| 520 | |a Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. | ||
| 650 | 7 | |a renal norepinephrine concentration |2 Elsevier | |
| 650 | 7 | |a pathology |2 Elsevier | |
| 650 | 7 | |a renal denervation |2 Elsevier | |
| 650 | 7 | |a immunohistochemical stains |2 Elsevier | |
| 650 | 7 | |a pre-clinical |2 Elsevier | |
| 700 | 1 | |a Ladich, Elena |4 oth | |
| 700 | 1 | |a Edelman, Elazer R. |4 oth | |
| 700 | 1 | |a Markham, Peter |4 oth | |
| 700 | 1 | |a Stanley, James R.L. |4 oth | |
| 700 | 1 | |a Keating, John |4 oth | |
| 700 | 1 | |a Kolodgie, Frank D. |4 oth | |
| 700 | 1 | |a Virmani, Renu |4 oth | |
| 700 | 1 | |a Joner, Michael |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Li, Bao-jia ELSEVIER |t Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application |d 2023 |d a journal of the American College of Cardiology |g New York, NY |w (DE-627)ELV00979817X |
| 773 | 1 | 8 | |g volume:7 |g year:2014 |g number:10 |g pages:1184-1193 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcin.2014.04.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.45 |j Werkstoffe mit besonderen Eigenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 7 |j 2014 |e 10 |h 1184-1193 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
k s ks |
|---|---|
| matchkey_str |
sakakurakenichiladichelenaedelmanelazerr:2014----:ehdlgcltnadztofrhpelnclvlainfea |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
51.00 51.45 |
| publishDate |
2014 |
| allfields |
10.1016/j.jcin.2014.04.024 doi GBVA2014011000015.pica (DE-627)ELV033920184 (ELSEVIER)S1936-8798(14)01188-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl Sakakura, Kenichi verfasserin aut Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation 2014transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Elsevier Ladich, Elena oth Edelman, Elazer R. oth Markham, Peter oth Stanley, James R.L. oth Keating, John oth Kolodgie, Frank D. oth Virmani, Renu oth Joner, Michael oth Enthalten in Elsevier Li, Bao-jia ELSEVIER Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application 2023 a journal of the American College of Cardiology New York, NY (DE-627)ELV00979817X volume:7 year:2014 number:10 pages:1184-1193 extent:10 https://doi.org/10.1016/j.jcin.2014.04.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ AR 7 2014 10 1184-1193 10 045F 610 |
| spelling |
10.1016/j.jcin.2014.04.024 doi GBVA2014011000015.pica (DE-627)ELV033920184 (ELSEVIER)S1936-8798(14)01188-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl Sakakura, Kenichi verfasserin aut Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation 2014transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Elsevier Ladich, Elena oth Edelman, Elazer R. oth Markham, Peter oth Stanley, James R.L. oth Keating, John oth Kolodgie, Frank D. oth Virmani, Renu oth Joner, Michael oth Enthalten in Elsevier Li, Bao-jia ELSEVIER Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application 2023 a journal of the American College of Cardiology New York, NY (DE-627)ELV00979817X volume:7 year:2014 number:10 pages:1184-1193 extent:10 https://doi.org/10.1016/j.jcin.2014.04.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ AR 7 2014 10 1184-1193 10 045F 610 |
| allfields_unstemmed |
10.1016/j.jcin.2014.04.024 doi GBVA2014011000015.pica (DE-627)ELV033920184 (ELSEVIER)S1936-8798(14)01188-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl Sakakura, Kenichi verfasserin aut Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation 2014transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Elsevier Ladich, Elena oth Edelman, Elazer R. oth Markham, Peter oth Stanley, James R.L. oth Keating, John oth Kolodgie, Frank D. oth Virmani, Renu oth Joner, Michael oth Enthalten in Elsevier Li, Bao-jia ELSEVIER Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application 2023 a journal of the American College of Cardiology New York, NY (DE-627)ELV00979817X volume:7 year:2014 number:10 pages:1184-1193 extent:10 https://doi.org/10.1016/j.jcin.2014.04.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ AR 7 2014 10 1184-1193 10 045F 610 |
| allfieldsGer |
10.1016/j.jcin.2014.04.024 doi GBVA2014011000015.pica (DE-627)ELV033920184 (ELSEVIER)S1936-8798(14)01188-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl Sakakura, Kenichi verfasserin aut Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation 2014transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Elsevier Ladich, Elena oth Edelman, Elazer R. oth Markham, Peter oth Stanley, James R.L. oth Keating, John oth Kolodgie, Frank D. oth Virmani, Renu oth Joner, Michael oth Enthalten in Elsevier Li, Bao-jia ELSEVIER Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application 2023 a journal of the American College of Cardiology New York, NY (DE-627)ELV00979817X volume:7 year:2014 number:10 pages:1184-1193 extent:10 https://doi.org/10.1016/j.jcin.2014.04.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ AR 7 2014 10 1184-1193 10 045F 610 |
| allfieldsSound |
10.1016/j.jcin.2014.04.024 doi GBVA2014011000015.pica (DE-627)ELV033920184 (ELSEVIER)S1936-8798(14)01188-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl Sakakura, Kenichi verfasserin aut Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation 2014transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Elsevier Ladich, Elena oth Edelman, Elazer R. oth Markham, Peter oth Stanley, James R.L. oth Keating, John oth Kolodgie, Frank D. oth Virmani, Renu oth Joner, Michael oth Enthalten in Elsevier Li, Bao-jia ELSEVIER Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application 2023 a journal of the American College of Cardiology New York, NY (DE-627)ELV00979817X volume:7 year:2014 number:10 pages:1184-1193 extent:10 https://doi.org/10.1016/j.jcin.2014.04.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ AR 7 2014 10 1184-1193 10 045F 610 |
| language |
English |
| source |
Enthalten in Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application New York, NY volume:7 year:2014 number:10 pages:1184-1193 extent:10 |
| sourceStr |
Enthalten in Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application New York, NY volume:7 year:2014 number:10 pages:1184-1193 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffe mit besonderen Eigenschaften |
| institution |
findex.gbv.de |
| topic_facet |
renal norepinephrine concentration pathology renal denervation immunohistochemical stains pre-clinical |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application |
| authorswithroles_txt_mv |
Sakakura, Kenichi @@aut@@ Ladich, Elena @@oth@@ Edelman, Elazer R. @@oth@@ Markham, Peter @@oth@@ Stanley, James R.L. @@oth@@ Keating, John @@oth@@ Kolodgie, Frank D. @@oth@@ Virmani, Renu @@oth@@ Joner, Michael @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00979817X |
| dewey-sort |
3610 |
| id |
ELV033920184 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033920184</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625195351.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcin.2014.04.024</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014011000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033920184</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1936-8798(14)01188-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sakakura, Kenichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal norepinephrine concentration</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pathology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal denervation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">immunohistochemical stains</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pre-clinical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ladich, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edelman, Elazer R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Markham, Peter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stanley, James R.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Keating, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kolodgie, Frank D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Virmani, Renu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joner, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Li, Bao-jia ELSEVIER</subfield><subfield code="t">Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application</subfield><subfield code="d">2023</subfield><subfield code="d">a journal of the American College of Cardiology</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV00979817X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:1184-1193</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcin.2014.04.024</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.45</subfield><subfield code="j">Werkstoffe mit besonderen Eigenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2014</subfield><subfield code="e">10</subfield><subfield code="h">1184-1193</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Sakakura, Kenichi |
| spellingShingle |
Sakakura, Kenichi ddc 610 ddc 600 bkl 51.00 bkl 51.45 Elsevier renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation |
| authorStr |
Sakakura, Kenichi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00979817X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 600 - Technology 670 - Manufacturing |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical Elsevier |
| topic |
ddc 610 ddc 600 bkl 51.00 bkl 51.45 Elsevier renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical |
| topic_unstemmed |
ddc 610 ddc 600 bkl 51.00 bkl 51.45 Elsevier renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical |
| topic_browse |
ddc 610 ddc 600 bkl 51.00 bkl 51.45 Elsevier renal norepinephrine concentration Elsevier pathology Elsevier renal denervation Elsevier immunohistochemical stains Elsevier pre-clinical |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e l el e r e er ere p m pm j r s jr jrs j k jk f d k fd fdk r v rv m j mj |
| hierarchy_parent_title |
Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application |
| hierarchy_parent_id |
ELV00979817X |
| dewey-tens |
610 - Medicine & health 600 - Technology 670 - Manufacturing |
| hierarchy_top_title |
Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00979817X |
| title |
Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation |
| ctrlnum |
(DE-627)ELV033920184 (ELSEVIER)S1936-8798(14)01188-1 |
| title_full |
Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation |
| author_sort |
Sakakura, Kenichi |
| journal |
Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application |
| journalStr |
Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
1184 |
| author_browse |
Sakakura, Kenichi |
| container_volume |
7 |
| physical |
10 |
| class |
610 610 DE-600 600 670 VZ 51.00 bkl 51.45 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sakakura, Kenichi |
| doi_str_mv |
10.1016/j.jcin.2014.04.024 |
| dewey-full |
610 600 670 |
| title_sort |
methodological standardization for the pre-clinical evaluation of renal sympathetic denervation |
| title_auth |
Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation |
| abstract |
Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. |
| abstractGer |
Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. |
| abstract_unstemmed |
Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
10 |
| title_short |
Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation |
| url |
https://doi.org/10.1016/j.jcin.2014.04.024 |
| remote_bool |
true |
| author2 |
Ladich, Elena Edelman, Elazer R. Markham, Peter Stanley, James R.L. Keating, John Kolodgie, Frank D. Virmani, Renu Joner, Michael |
| author2Str |
Ladich, Elena Edelman, Elazer R. Markham, Peter Stanley, James R.L. Keating, John Kolodgie, Frank D. Virmani, Renu Joner, Michael |
| ppnlink |
ELV00979817X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jcin.2014.04.024 |
| up_date |
2024-07-06T19:48:25.646Z |
| _version_ |
1803860370415157248 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033920184</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625195351.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcin.2014.04.024</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014011000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033920184</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1936-8798(14)01188-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sakakura, Kenichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter ablation of renal autonomic nerves is a viable option for the treatment of resistant arterial hypertension; however, structured pre-clinical evaluation with standardization of analytical procedures remains a clear gap in this field. Here we discuss the topics relevant to the pre-clinical model for the evaluation of renal denervation (RDN) devices and report methodologies and criteria toward standardization of the safety and efficacy assessment, including histopathological evaluations of the renal artery, periarterial nerves, and associated periadventitial tissues. The pre-clinical swine renal artery model can be used effectively to assess both the safety and efficacy of RDN technologies. Assessment of the efficacy of RDN modalities primarily focuses on the determination of the depth of penetration of treatment-related injury (e.g., necrosis) of the periarterial tissues and its relationship (i.e., location and distance) and the effect on the associated renal nerves and the correlation thereof with proxy biomarkers including renal norepinephrine concentrations and nerve-specific immunohistochemical stains (e.g., tyrosine hydroxylase). The safety evaluation of RDN technologies involves assessing for adverse effects on tissues local to the site of treatment (i.e., on the arterial wall) as well as tissues at a distance (e.g., soft tissue, veins, arterial branches, skeletal muscle, adrenal gland, ureters). Increasing experience will help to create a standardized means of examining all arterial beds subject to ablative energy and in doing so enable us to proceed to optimize the development and assessment of these emerging technologies.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal norepinephrine concentration</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pathology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal denervation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">immunohistochemical stains</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pre-clinical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ladich, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edelman, Elazer R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Markham, Peter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stanley, James R.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Keating, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kolodgie, Frank D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Virmani, Renu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joner, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Li, Bao-jia ELSEVIER</subfield><subfield code="t">Nanosecond pulsed laser annealing of Cu/Ag/AZO multilayer thin films for performance improvement and transparent heater application</subfield><subfield code="d">2023</subfield><subfield code="d">a journal of the American College of Cardiology</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV00979817X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:1184-1193</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcin.2014.04.024</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.45</subfield><subfield code="j">Werkstoffe mit besonderen Eigenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2014</subfield><subfield code="e">10</subfield><subfield code="h">1184-1193</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3998547 |